A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model

[1] Desgrandchamps F(2006)Management of non-complicated BPH: proposition of a renewed decision tree World J Urol 24 367-370

[2] de la Taille A(2004)EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) Eur Urol 46 547-554

[3] Azzouzi A-R(2004)Guideline for the primary care management of male lower urinary tract symptoms BJU Int 93 985-990

[4] Fourmarier M(2006)Prostate disorders in an apparently normal Nigerian population 1: Prevalence Biokemistri 18 127-132

[5] Haillot O(2003)The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia N Engl J Med 349 2387-2398

[6] Lukacs B(2011)Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin Patient Relat Outcome Meas 2 71-79

[7] Saussine C(2002)Managing benign prostatic hyperplasia Am Fam Physician 66 77-90

[8] Madersbacher S(2011)Update on AUA guideline on the management of benign prostatic hyperplasia J Urol 185 1793-1803

[9] Alivizatos G(2004)5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery Eur Urol 45 620-627

[10] Nordling J(1999)A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 1-13

[1] Desgrandchamps F(2006)Management of non-complicated BPH: proposition of a renewed decision tree World J Urol 24 367-370

[2] de la Taille A(2004)EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) Eur Urol 46 547-554

[3] Azzouzi A-R(2004)Guideline for the primary care management of male lower urinary tract symptoms BJU Int 93 985-990

[4] Fourmarier M(2006)Prostate disorders in an apparently normal Nigerian population 1: Prevalence Biokemistri 18 127-132

[5] Haillot O(2003)The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia N Engl J Med 349 2387-2398

[6] Lukacs B(2011)Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin Patient Relat Outcome Meas 2 71-79

[7] Saussine C(2002)Managing benign prostatic hyperplasia Am Fam Physician 66 77-90

[8] Madersbacher S(2011)Update on AUA guideline on the management of benign prostatic hyperplasia J Urol 185 1793-1803

[9] Alivizatos G(2004)5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery Eur Urol 45 620-627

[10] Nordling J(1999)A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 1-13